Logo for Monte Rosa Therapeutic Inc

Monte Rosa Therapeutic Investor Relations Material

Latest events

Logo for Monte Rosa Therapeutic Inc

Q4 2024

Monte Rosa Therapeutic
Logo for Monte Rosa Therapeutic

Q4 2024

20 Mar, 2025
Logo for Monte Rosa Therapeutic

Q3 2024

7 Nov, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Monte Rosa Therapeutic Inc

Access all reports
Monte Rosa Therapeutics Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs). These small molecules are designed to selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation processes. The company targets a range of therapeutic areas, including oncology, autoimmune, and inflammatory diseases. Monte Rosa utilizes its proprietary QuEEN platform, which integrates proteomics, structural biology, AI, and machine learning, to rapidly identify and develop highly selective protein degraders. The company operates out of Boston, Massachusetts, with additional research facilities in Basel, Switzerland. Its shares trade on the NASDAQ.